

☰ Explore

mint



e-paper

Subscribe

Sign in

OPEN APP

Home

Latest

Trending

Premium

Coronavirus Vaccine  
Tracker

Coronavirus

Home > Companies > News > Covid-19: Dr Reddy's, Cipla, 3 more pharma firms partne...

## Covid-19: Dr Reddy's, Cipla, 3 more pharma firms partner for clinical trial of oral anti-viral drug

Mint India Investment Summit 2021

Market Dashboard

Long Story

Plain Facts

Mark To Market

Primer



Representational image

1 min read . Updated: 29 Jun 2021, 04:25 PM IST

### Livemint

- The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India



Advertisement

OPEN APP

× Close

Indian pharma majors including [Lundbeck's](#) Laboratories and Sun Pharma have collaborated for clinical trial of investigational oral anti-viral drug Molnupiravir for Covid-19. The five companies: [Cipla](#), Dr Reddy's, Emcure, Sun Pharma and Torrent Pharma announced on Tuesday that they will collaborate for the clinical trial of the investigational oral anti-viral drug Molnupiravir for the treatment of mild [Covid-19](#) in an outpatient setting in India.

Between March and April this year, these five pharma companies had individually entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low and middle-income countries (LMICs).

The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India.

OPEN APP

As per the directive of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization, Dr. Reddy's will conduct the clinical trial using its product, and the other four pharma companies will be required to demonstrate equivalence of their product to the product used by Dr Reddy's in its clinical trial, the statement said.

Following the clinical trial protocol approval given by the Drugs Controller General of India, the clinical trial will be conducted for the treatment of mild Covid-19 in an outpatient setting. It is expected to take place between June and September this year across India with the recruitment of 1,200 patients.

Molnupiravir is an oral anti-viral that inhibits the replication of multiple RNA viruses including SARS-CoV-2. It is presently being studied by MSD, through a collaboration with Ridgeback Biotherapeutics, in a Phase III trial for the treatment of non-hospitalized patients with confirmed COVID-19 globally.

OPEN APP

MINT PREMIUM

See All >

PREMIUM

PREMIUM

PREMIUM